

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Simvastatin

March 17, 2026

Therapeutic category

Agents for hyperlipidemias

Non-proprietary name

Simvastatin

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.
 This English version is intended to be a reference material to provide convenience for users.
 In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current			Revision		
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) Patients receiving itraconazole, miconazole, posaconazole, atazanavir, saquinavir mesylate, preparations containing cobicistat			2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) Patients receiving itraconazole, miconazole, posaconazole, atazanavir, saquinavir mesylate, preparations containing cobicistat, <u>ceritinib</u>		
10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the following.)			10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the following.)		
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
Atazanavir Saquinavir mesylate Preparations containing cobicistat	Serious adverse reactions such as myopathy, including rhabdomyolysis, may occur.	These drugs inhibit CYP3A4, thereby suppressing the metabolism of this drug.	Atazanavir Saquinavir mesylate Preparations containing <u>Ceritinib</u>	Serious adverse reactions such as myopathy, including rhabdomyolysis, may occur.	These drugs inhibit CYP3A4, thereby suppressing the metabolism of this drug.